|
 |
David A. Saperstein, MD  Associate Professor of Ophthalmology  Administrative Assistant : (206) 221-6520  FAX: (206) 543-4414   To schedule patient appointments:  University of Washington Eye Center  (206) 598-4011  Harborview Medical Center Eye Clinic  (206) 731-3225  Visit My Practice Online |
|
|
|
|
|
|
|||
|
EDUCATION |
|||
| 1983 | BS, Electrical Engineering, George Washington University, Washington, D.C. | ||
| 1987 | MD, Pennsylvania State University, College of Medicine, Hershey, Pa. | ||
|
POSTGRADUATE TRAINING |
|||
| 1987-1988 | Internship, Boston University Hospital, Boston, Mass. | ||
| 1988-1990 | National Research Science Award Fellow, National Retinitis Pigmentosa Foundation Fellow, National Eye Institute, NIH, Bethesda, Md. | ||
| 1990-1993 | Residency in Ophthalmology, Saint Louis University School of Medicine, St. Louis, Mo. | ||
| 1992-1993 | Chief Resident, Department of Ophthalmology, Saint Louis University School of Medicine, St. Louis, Mo. | ||
| 1993-1995 | Vitreoretinal Medicine and Surgery Fellow, Department of Ophthalmology, Emory University, Atlanta, Ga. | ||
|
FACULTY POSITIONS HELD |
|||
| 1995-2000 | Assistant Professor, Department of Ophthalmology, Emory University, Atlanta, Ga. | ||
| 1999-2000 | Visiting Scientist, Yerkes Primate Research Center, Atlanta, Ga. | ||
| 2000-2003 | Assistant Professor, Department of Ophthalmology, University of Washington, Seattle. | ||
| 2003-date | Assistant Professor, Department of Ophthalmology, University of Washington, Seattle. | ||
|
HOSPITAL POSITIONS HELD |
|||
| 2000-date | Active Medical Staff, University of Washington Medical Center, Seattle | ||
| 2000-date | Associate Medical Staff, Harborview Medical Center, Seattle, Wash. | ||
| 2000-date | Consultant, Veterans' Affairs Puget Sound Health Care System, Seattle, Wash. | ||
| 2000-date | Courtesy Medical Staff, Children's Hospital & Regional Medical Center, Seattle, Wash. | ||
|
HONORS AND AWARDS |
|||
| 1987 | National Research Scientist Award, National Eye Institute | ||
| 1993-1994 | Heed Ophthalmic Fellowship, Department of Ophthalmology, Emory University, Atlanta, Ga. | ||
| 1998 | T. Wayne Robertson Career Development Award, The Foundation Fighting Blindness | ||
|
BOARD CERTIFICATION |
|||
| 1995 | Diplomate, American Board of Ophthalmology | ||
|
CURRENT LICENSURE |
|||
| Washington | |||
|
SELECTED PROFESSIONAL MEMBERSHIPS |
|||
American Academy of Ophthalmology (AAO) |
|||
SELECTED FUNDED BASIC AND CLINICAL RESEARCH PROJECTS | |||
Clinical Investigations 9/95- 2000 Age-Related Eye Disease Study (AREDS) Clinical Investigator, Funded by the National Eye Institute. 1/98-1/00 Photodynamic Therapy for Macular Degeneration Study (VIP) Ciba Vision Ophthalmics/QALT Ltd., $137,700/yr 6/98-6/00 Photodynamic Therapy for Ocular Histopasmosis Study (OHS) Ciba Vision Ophthalmics/QALT Ltd.,$137,700/yr 8/99-2000 Radiation Therapy for Age-Related Macular Degeneration Principal Investigator at Emory University Funding for pilot study approved by NEI. 7/00-date PKC 412, Diabetic Macular Edema Phase II Study, Novartis Ophthalmics ($50,000) 9/01-date Verteporfin Early Retreatment Study for Age-Related Macular Degeneration, Novartis Ophthalmics ($125/000/yr) 2003-date Verteporfin in Occult (VIO) Choridal Neovascularization Secondary to Age-Related Macular Degeneration, QLT Inc. ($100,000/yr) 2003-date Gene Therapy Using AD-PEDF Phase I Clinical Trial, Gen-Vec, Inc. ($60,000/yr) Basic Science 9/95 – 8/00 Physician/Scientist Award (K-11EY0347), National Eye Institute, NIH “Biologically active liposomes” $60,000 first year, $102,000 2nd yr, $120,000 3rd yr (~$600,000 Total) 3/98-9/04 Wayne T. Robertson, Young Investigator Award, Foundation Fighting Blindness “Non-viral methods for retinal gene therapy” $375,000 3/99 Veterans' Affairs, Atlanta , Ga. , Department of rehabilitation “Eccentric viewing low vision device, program development grant”$16,000 (Co-PIs: Ron Schuchard and Gale Watson). 9/99-9/02 Macular Vision Foundation/Ronald McDonald House “Towards a Primate Model for Gene Therapy for Macular Degeneration” $80,000/yr ($240,000) (Co-investigator); PI: William Hauswirth, University of Florida . 12/00-9/02 AMD Basic Science grant from Jim Lea ($127,000) 3/02 – 2/05 National Eye Institute, NIH “Recombinant Baculovirus as a Vector to Transfer Genes in Ocular Tissues” (Co-PI Francoise Haeseleer, Ph.D.) 100,000/yr (300,000) R03 EY13726-01 5/02 – 4/07 National Eye Institute, NIH “SCA7 Retinal Degeneration: Molecular Basis & Therapy” Principle investigator: Albert La Spada, MD. PhD, (Saperstein as Coinvestigator, 10% effort) R01 EY14061 3/04- 3/06 AMD Basic Science grant from Jim Lea ($306,000) | |||
PATENTS |
|||
Patent U.S. #5919158: Lens defogging device for vitreoretinal surgery in pseudophakes Patent U.S. #6155682: Apparatus and methods for improving vision damaged by retinal degeneration Patent U.S. pending Cis-retinoids for the treatment of AMD, aging and LCA |
|||
COMMUNITY SERVICE |
|||
|
|||
RECENT SIGNIFICANT PUBLICATIONS | |||
|
Age-Related Eye Disease Study Research Group: Risk factors associated with age-related nuclear and cortical cataract: a case-control study. AREDS Report No. 5. Ophthalmology , 2001;108:1400-8. Age-Related Eye Disease Study Research Group. The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the age-related eye disease study: AREDS Report No. 7. Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. AREDS Report No. 8. Arch Ophthalmol 2001;119:1417-36. Verteporfin in Photodynamic Therapy Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial--VIP Report #1. Arch Ophthalmol 2001; 108: 841-52. Haeseleer F, Imanishi Y , Saperstein DA, Palczewski K: Gene transfer mediated by recombinant baculoviruses into mouse eye. IOVS 2001;42:3294-3300. Imanishi Y, Li N, Sokal I, Sowa ME, Lichtarge O, Wensel TG, Saperstein DA, Baehr W, Palczewski K: Characterization of retinal guanylyl cyclase-activating protein 3 (GCAP3) from zebrafish to man . Eur J Neurosci 2002;15:63-78 Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neo-vascularization due to age-related macular degeneration and other causes. Retina 2002;22:6-18. Saperstein DA, Rosenfeld PJ, Bressler NM , Rosa RH Jr, Sickenberg M, Sternberg P Jr, Aaberg TM Sr, Aaberg TM Jr, Reaves TA, for the Verteporfin in Ocular Histoplasmosis (VOH) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the Ocular Histoplasmosis Syndrome: One-year results of an uncontrolled, prospectie case series. Ophthalmology 2002;109:1499-1505. Fotiadis D, Liang Y, Filipek S , Saperstein DA, Engel A, Palczewski K: Rhodopsin forms paracrystalline arrays of dimers in native disk membranes. Nature . 2003, Jan 9:421(6919) 127-8. Fotiadis D, Liang Y, Filipek S , Saperstein DA, Engel A, Palczewski K: Rhodopsin forms paracrystalline arrays of dimers in native disk membranes. (editorial response) Nature 2003:421;127-8. Rosenfeld PJ, Saperstein, DA , Bressler NM , Reaves TA, Sickenberg M, Rosa RH, Sternberg PS Jr, Aaberg, TM Sr, Aaberg TM Jr. Photodynamic Therapy of Subfoveal Choroidal Neovascularization with Verteporfin in the Ocular Histoplasmosis Syndrome: Two-Year Results of an Uncontrolled, Open-Label Clinical Study. Ophthalmology 2004;111L1725-34. | |||
|
|
||
|
© 1997-2003 University of Washington Department of Ophthalmology Return to Top of Page University of Washington School of Medicine Home Page University of Washington Home Page Ophthalmology Home Page |